SCHEMBL5756488

SCHEMBL5756488

Cc1cccc2c(O)nc(O)nc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 5/20 0.44
PARP1 P09874 3/20 0.44
RAD52 P43351 2/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
TNKS O95271 2/20 0.43
TNKS2 Q9H2K2 2/20 0.43
KDM4E B2RXH2 5/20 0.42
CYP2A6 P11509 2/20 0.41
CYP1A2 P05177 1/20 0.41
ALDH1A1 P00352 4/20 0.40
GAA P10253 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
TP53 P04637 1/20 0.40
HPGD P15428 2/20 0.40
TDP1 Q9NUW8 1/20 0.39
PSMD14 O00487 1/20 0.39
MITF O75030 1/20 0.39
LMNA P02545 1/20 0.39
POLB P06746 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27393825 0.84 CYP2A6 (0.46) ELANEPARP1RAD52MEN1KMT2A
SCHEMBL19758771 0.84 CYP2A6 (0.38) CYP2A6CYP1A2ALDH1A1GAAMAPT
SCHEMBL13975076 0.81 HRH4 (0.51) ELANEPARP1RAD52MEN1KMT2A
SCHEMBL12282628 0.81 RAD52 (0.45) ELANEPARP1RAD52MEN1KMT2A
SCHEMBL17867403 0.79 CYP1A2 (0.47) PARP1KMT2ATNKSTNKS2KDM4E
SCHEMBL14391599 0.76 CYP1A2 (0.31) CYP1A2
SCHEMBL558684 0.76 MAPT (0.40) MEN1KMT2AKDM4ECYP1A2ALDH1A1
SCHEMBL15845928 0.76 NR4A2 (0.43) PARP1TNKSTNKS2KDM4ECYP2A6
SCHEMBL15857826 0.76 KDM4E (0.45) PARP1MEN1KMT2ATNKSTNKS2
SCHEMBL30615143 0.75 KDM4E (0.44) MEN1KMT2AKDM4EALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1218358-B1 THERAPEUTIC QUINAZOLINE COMPOUNDS ASTRAZENECA AB (SE) 2006-09-13 EP disclosed
EP-1218358-A1 THERAPEUTIC QUINAZOLINE COMPOUNDS AstraZeneca AB (SE) 2002-07-03 EP disclosed
US-6399603-B1 QUINAZOLINES; RETARDING APOPTOSIS IN CELLS; INHIBITING CLEAVAGE OF PROTEIN SUBSTRATES BY CASPASE-3; CHEMICAL AND HYDROLYTIC STABILITY ASTRAZENECA AB (SE) 2002-06-04 US disclosed
US-6316482-B1 FOR THERAPY AND PROPHYLAXIS OF HYPERTENSION, HEART FAILURE, RENAL INSUFFICIENCY, EDEMA, ASCITES, VASOPRESSIN PARASECRETION SYNDROME, HEPATOCIRRHOSIS, HYPONATREMIA, HYPOKALEMIA, DIABETIC, CIRCULATION DISORDER, CEREBROVASCULAR DISEASE FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-11-13 US disclosed
WO-2001021598-A1 THERAPEUTIC QUINAZOLINE COMPOUNDS ASTRAZENECA AB (SE) 2001-03-29 WO disclosed
US-6207693-B1 Benzamide derivatives having a vasopressin antagonistic activity FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-03-27 US disclosed
EP-0946519-A1 BENZAMIDE DERIVATIVES HAVING A VASOPRESSIN ANTAGONISTIC ACTIVITY FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1999-10-06 EP disclosed
WO-1998024771-A1 BENZAMIDE DERIVATIVES HAVING A VASOPRESSIN ANTAGONISTIC ACTIVITY FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1998-06-11 WO disclosed